Literature DB >> 10721013

Sensitivity and perspective in the valuation of health status: whose values count?

G A De Wit1, J J Busschbach, F T De Charro.   

Abstract

The literature was studied on the existence of differences in valuation for hypothetical and actual health states between patients and other-rater groups. It was found that nine different study designs have been used to study this question and two of these designs were applied in a study involving dialysis patients and other rater groups. In the first study, both dialysis patients and students had to value hypothetical health states with Standard Gamble (SG) and Time Trade Off (TTO). Patients assigned higher values to hypothetical health states than students did. In the second study, dialysis patients who were being treated with four different dialysis modalities were asked to value their own health state with SG, TTO and a visual analogue scale (EQ(VAS)), and to describe their health state on the EQ-5D(profile). Several EQ-5D(index) values (health index values derived from general population samples) were calculated for the four dialysis treatment groups, based on the EQ-5D(profile). These health indexes could discriminate between treatment groups, according to clinical impressions. Treatment groups could not be differentiated based on patients' valuations of own health state. The results suggest that general population samples, using EQ-5D(index) values, may be more able to discriminate between patient groups than the patients themselves are. The implications of this finding for valuation research and policy-making are discussed. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10721013     DOI: 10.1002/(sici)1099-1050(200003)9:2<109::aid-hec503>3.0.co;2-l

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  50 in total

1.  Understanding differences between self-ratings and population ratings for health in the EuroQOL.

Authors:  Ralph P Insinga; Dennis G Fryback
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

2.  Comparison of hypothetical and experienced EQ-5D valuations: relative weights of the five dimensions.

Authors:  Kim Rand-Hendriksen; Liv Ariane Augestad; Ivar Sønbø Kristiansen; Knut Stavem
Journal:  Qual Life Res       Date:  2011-09-20       Impact factor: 4.147

3.  Health-related quality of life as a predictor of mortality among survivors of AKI.

Authors:  Vilija R Joyce; Mark W Smith; Kirsten L Johansen; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

Review 4.  Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives.

Authors:  A Simon Pickard; Sara J Knight
Journal:  Med Care       Date:  2005-05       Impact factor: 2.983

5.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Loss aversion and cost effectiveness of healthcare programmes: whose aversion counts anyway?

Authors:  Johan L Severens; J L Hans Severens
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO.

Authors:  F E van Nooten; X Koolman; J J V Busschbach; W B F Brouwer
Journal:  Qual Life Res       Date:  2013-08-14       Impact factor: 4.147

Review 8.  Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research.

Authors:  Patricia Cubi-Molla; Koonal Shah; Kristina Burström
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 9.  Using QALYs in cancer: a review of the methodological limitations.

Authors:  Martina Garau; Koonal K Shah; Anne R Mason; Qing Wang; Adrian Towse; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

Review 10.  A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.

Authors:  Hirsch S Ruchlin; Ralph P Insinga
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.